Track market-moving stories before they get noisy

Key Takeaways LLY's TRIUMPH-2 study showed retatrutide drove up to 20.8% weight loss and A1C reductions at 80 weeks.TRIUMPH-3 showed LLY's retatrutide delivered up to 22.6% weight loss in severe obesity at 80 weeks.LLY said the latest data will support filings for retatrutide in the United States in Q1 2027. Eli Lilly (LLY - Free Report) announced positive top-line data from two late-stage studies evaluating its next-generation, experimental triple-acting incretin, retatrutide, in patients with obesity or those who are overweight as well as some of its most serious complications – type II diabetes and established cardiovascular disease.

The phase III TRIUMPH-2 study is under a basket design evaluating the safety and efficacy of once weekly retatrutide versus placebo in participants with type II diabetes and obesity or those who are overweight. Patients in the study were randomized in a 1:1:1:1 ratio to receive retatrutide (4 mg, 9 mg, 12 mg) or placebo over a period of 80 weeks.

Meanwhile, the phase III TRIUMPH-3 study is evaluating the safety and efficacy of once-weekly retatrutide versus placebo in participants with severe obesity and established cardiovascular disease. Patients in this study were randomized in a 1:1:2 ratio to receive retatrutide 9 mg, 12 mg, or placebo over a period of 80 weeks.

Year to date, Lilly’s shares have risen 10.7% compared with the industry’s 11.8% rally.

Image Source: Zacks Investment Research

LLY’s Retatrutide Scores Big in Latest Obesity StudiesData from the TRIUMPH-2 study showed that treatment with all doses of retatrutide (4 mg, 9 mg, 12 mg) led to substantial weight loss and improved glycemic control at 80 weeks in adults with type II diabetes and obesity or overweight. Treatment with retatrutide 4 mg, 9 mg, and 12 mg led to an average weight loss of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, in the given patient population, at 80 weeks.

Data from the TRIUMPH-3 study showed that treatment with retatrutide (9 mg, 12 mg) led to an average weight loss of up to 55.8 lbs (22.6%) at 80 weeks in patients with severe obesity and established cardiovascular disease.

Importantly, treatment with retatrutide meaningfully reduced certain cardiovascular risk factors, with the highest dose (12mg) delivering average reductions of 37% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 7.5 in (19.0 cm) in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP) in the TRIUMPH-3 study.

LLY’s Previous Phase III Wins With RetatrutideWe remind investors that the success of the phase III TRIUMPH-2 and TRIUMPH-3 obesity studies marks the fourth and fifth positive phase III data readout for Eli Lilly’s retatrutide.

In May 2026, Lilly announced that the phase III TRIUMPH-1 study, which evaluated the efficacy and safety of three doses (4 mg, 9 mg and 12 mg) of retatrutide for 80 weeks against placebo in adults with obesity or overweight, met its primary endpoint.

In March 2026, Eli Lilly reported that the late-stage TRANSCEND-T2D-1 study of once-weekly retatrutide in adults with T2D and inadequate glycemic control met its primary endpoint.

In late 2025, Eli Lilly reported meeting all primary and key secondary endpoints in the late-stage TRIUMPH-4 study, which evaluated the candidate in adults with obesity or overweight and knee osteoarthritis, without diabetes.

Retatrutide is being evaluated in several phase III studies for obesity and overweight with at least one weight-related medical problem, T2D, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea (OSA), chronic low back pain, cardiovascular and renal outcomes and metabolic dysfunction-associated steatotic liver disease.

Importantly, with the latest results from the TRIUMPH-2 and TRIUMPH-3 studies, Lilly now has the data package that will support global regulatory filings for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and OSA.

The company plans to submit a biologics license application for retatrutide to the FDA in the first quarter of 2027. However, the timeline seems a little delayed from the prior expectation of filing retatrutide for obesity and knee osteoarthritis pain in 2026. If approved, retatrutide could become another multibillion-dollar product.

Retatrutide represents a new generation of “triple-action” therapy targeting three biological pathways — GLP-1, GIP and glucagon — potentially offering greater weight-loss and metabolic benefits than existing medicines, which mostly act on one or two biological pathways. LLY’s approved obesity drug Zepbound targets GLP-1 and GIP, while Novo Nordisk’s (NVO - Free Report) blockbuster obesity drug Wegovy activates only GLP-1.

LLY’s Competition in the Obesity SpaceEli Lilly and Novo Nordisk presently dominate the obesity market.

Novo Nordisk gained approval for an oral version of its obesity drug, Wegovy, in December 2025 and launched the pill in January 2026. In early April 2026, Lilly gained FDA approval for its once-daily oral GLP-1 pill Foundayo (orforglipron) for treating obesity.

Smaller biotech firms, like Viking Therapeutics (VKTX - Free Report) and Structure Therapeutics (GPCR - Free Report) , are also advancing GLP-1–based therapies to challenge the incumbents. Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed as both oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.

Structure Therapeutics’ phase II ACCESS study on its orally administered GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.

LLY’s Zacks RankEli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks

Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.

"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. We look forward to working with regulators as they evaluate this first-of-its-kind medicine."

In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight. Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.

TRIUMPH-2 Efficacy Estimand Results in Participants with Obesity and Type 2 Diabetes1

Primary Endpoint at 80 Weeks 

Retatrutide 4 mg

Retatrutide 9 mg

Retatrutide 12 mg

Placebo

Percent change in body weight from avg. baseline of 106.4 kg (234.6 lbs; BMI of 38.2 kg/m²)i

-12.7% (-13.5 kg; -29.8 lbs) 

-19.1% (-20.6 kg; -45.4 lbs) 

-20.8% (-22.5 kg; -49.6 lbs) 

-4.0% (-4.2 kg; -9.3 lbs)

Key Secondary Endpoint at 80 Weeks

Change in A1C from a baseline of 7.7%

-1.4‌%

-1.6‌%

-1.5‌%

-0.2‌%

iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint.

In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks.

In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).

In TRIUMPH-3, retatrutide meaningfully reduced certain cardiovascular risk factors, with the highest dose delivering average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 7.5 in (19.0 cm) in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP).

TRIUMPH-3 Efficacy Estimand Results in Participants with Severe Obesity and Established Cardiovascular Disease1

Primary Endpoint at 80 Weeks

Retatrutide 9 mg

Retatrutide 12 mg

Placebo

Percent change in body weight from avg. baseline of 111.4 kg (245.6 lbs; BMI of 40.4 kg/m²)

-21.6% (-23.9 kg; -52.7 lbs) 

-22.6% (-25.3 kg; -55.8 lbs) 

-3.2% (-3.5 kg; -7.7 lbs)

Additional Analysesi

In-Study

On-Treatment

Time to first occurrence of MACE-5

Hazard ratio = 0.82

95.0% CI: 0.55 to 1.22

Hazard ratio = 0.73

95.0% CI: 0.47 to 1.12

Time to first occurrence of MACE-3

Hazard ratio = 1.12

95.0% CI: 0.64 to 1.96

Hazard ratio = 0.92

95.0% CI: 0.51 to 1.65

iHazard ratio was estimated from Cox proportional hazards model comparing retatrutide (pooled 9 mg and 12 mg) vs. placebo; in-study analysis (pre-specified) includes events which occurred during the study treatment period regardless of adherence to retatrutide or placebo, while on-treatment analysis (not pre-specified) excludes events which occurred more than 35 days after discontinuing retatrutide or placebo.

In TRIUMPH-2, the most common adverse events with retatrutide (4 mg, 9 mg, 12 mg vs. placebo, respectively) were diarrhea (27.4%, 33.5%, 33.6% vs. 13.2%), nausea (13.7%, 20.8%, 28.0% vs. 8.0%), constipation (14.0%, 16.2%, 16.8% vs. 9.4%), decreased appetite (5.8%, 12.3%, 17.1% vs. 4.5%), and vomiting (5.5%, 10.2%, 15.7% vs. 4.2%). In TRIUMPH-3, the most common adverse events with retatrutide (9 mg, 12 mg vs. placebo, respectively) were diarrhea (30.1%, 24.4% vs. 8.7%), nausea (21.7%, 22.4% vs. 5.8%), constipation (18.0%, 15.7% vs. 7.1%), decreased appetite (13.5%, 14.5% vs. 3.0%), and hyperglycemia (3.9%, 3.1% vs. 13.4%). In TRIUMPH-2, the incidence of dysesthesia and urinary tract infections were 4.5%, 5.6%, 7.3% vs. 0.7% and 3.8%, 6.3%, 8.0% vs. 6.6% with retatrutide 4 mg, 9 mg, 12 mg vs. placebo, respectively. In TRIUMPH-3, the incidence of dysesthesia and urinary tract infections were 6.4%, 6.4% vs. 1.3% and 6.1%, 7.0% vs. 5.3% with retatrutide 9 mg, 12 mg vs. placebo, respectively. These events were generally mild to moderate, and the majority resolved during treatment. Discontinuation rates due to adverse events in TRIUMPH-2 were 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) with retatrutide, compared with 4.9% for placebo. Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg) with retatrutide, compared with 4.8% for placebo.

Detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals. Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.

About retatrutide
Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.

About TRIUMPH-2, TRIUMPH-3, and the TRIUMPH clinical trial program
TRIUMPH-2 (NCT05929079) is a Phase 3, 80-week, randomized, double-blind, and placebo-controlled trial under a basket design investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with type 2 diabetes and obesity or overweight. The study randomized 1,152 participants in a 1:1:1:1 ratio to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 4 mg (via steps at 2 mg and 4 mg), 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg). TRIUMPH-2 included a post-treatment follow-up period of four weeks.

TRIUMPH-3 (NCT05882045) is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with severe obesity (Class 2 or Class 3), defined as BMI ≥35 kg/m2, and established cardiovascular disease. The study randomized 1,949 participants in a 1:1:2 ratio to receive retatrutide 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg).

The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.

Endnotes:

The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only). FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com. 

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.  moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back. 

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep

sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time.  Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) [or goto www.zepbound.lilly.com].

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you. 

ZP CON BS 25FEB2026
Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with type 2 diabetes and obesity or overweight and adults with severe obesity and established cardiovascular disease, and the timeline for future readouts, presentations and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:  Niki Biro; [email protected] (Media)
                 Michael Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company

Americký farmaceutický gigant Eli Lilly oddálil termín podání žádosti o schválení retatrutidu, nové generace léku na obezitu. Zatímco dříve firma počítala s možností předložit registraci už letos, tak nyní očekává podání dokumentace v prvním čtvrtletí příštího roku. Důvodem je potřeba dokončit shromažďování a ověřování výrobních a kvalitativních dat, která požadují regulační úřady.

Odklad přichází navzdory tomu, že retatrutid dosáhl pozitivních výsledků ve dvou dalších klinických studiích třetí fáze. Podle společnosti léčba vedla k výraznému úbytku hmotnosti i zlepšení kontroly hladiny krevního cukru u pacientů s obezitou a závažnými přidruženými onemocněními, včetně diabetu 2. typu a kardiovaskulárních chorob.

V jedné ze studií dosáhli pacienti, kteří trpí obezitou a diabetem 2. typu, po 80 týdnech léčby průměrného snížení tělesné hmotnosti až o 20,8 procenta, což odpovídá přibližně 23 kilogramům. Právě tato skupina pacientů přitom obvykle mívá s hubnutím největší problémy, upozorňuje server CNBC.

Druhá studie sledovala osoby s těžkou obezitou a potvrzeným kardiovaskulárním onemocněním, ať už s diabetem či bez něj. V této skupině vedla léčba k průměrnému úbytku hmotnosti až o 22,6 procenta neboli o více než 25 kilogramů během 80 týdnů. Eli Lilly zároveň uvedla, že přípravek příznivě ovlivnil vybrané rizikové faktory související s kardiovaskulárními onemocněními.

Bezpečnostní profil přípravku podávaného injekčně jednou týdně podle společnosti odpovídá předchozím studiím. Nejčastěji hlášenými nežádoucími účinky byly průjem, nevolnost a zácpa. Jde o vedlejší účinky běžně spojované s celou skupinou léků založených na působení hormonů GLP-1.

Trojitý agonista

Retatrutid funguje jako trojitý agonista receptorů GLP-1, GIP a glukagonu, což je rozdíl oproti současné generaci léků založených na látce tirzepatid (GLP-1 a GIP), kterou obsahují léky Mounjaro a Zepbound. Právě kombinace hned tří mechanismů by podle dosavadních dat mohla přinášet výraznější účinek na regulaci chuti k jídlu i pocit nasycení než momentálně dostupné terapie.

Pro Eli Lilly představuje retatrutid klíčový přípravek ve snaze udržet si většinu tržního podílu před dánským konkurentem Novo Nordiskem na rostoucím trhu s léky na hubnutí a diabetes.

Analytici společnosti TD Cowen letos odhadli, že roční tržby retatrutidu by mohly do roku 2030 dosáhnout přibližně 3,8 miliardy dolarů.

Store

SubscribeSign In

My Subscriptions

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center

My Stock Lists

Email Preferences

Help & Support

Sign Out

Search stocks or keywords

Sections

My IBD

MARKET TREND

STOCK LISTS

STOCK RESEARCH

NEWSECONOMY

VIDEOS & PODCASTS

HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live

Recently Searched

Dell Leaps 9%, Rising Toward New High. Leads 16 New To IBD Best Stock Watchlists

Are Markets Due For A Reckoning? The Signs Pointing To Market Defensiveness

S&P 500 Stock Rockets Late On Earnings As Google Boosts Capex Eli Lilly (LLY) said Thursday it will delay filing for Food and Drug Administration approval of its next-gen weight-loss drug, retatrutide, until the first quarter. The delay is a "VERY GOOD thing," Evercore ISI analyst Umer Raffat said in a report. It will give the obesity kingpin more time to complete a bigger Chemistry, Manufacturing and Controls package for the…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Item 1 of 2 A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo/File Photo

[1/2]A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesOverweight or obese diabetes patients had 20.8% weight loss at high dose of retatrutidePatients with severe obesity and cardiovascular disease had weight loss of 22.6% at highest doseLilly ​plans FDA biologics application in first quarter 2027July 23 (Reuters) - Eli Lilly (LLY.N), opens new tab ‌on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in ​the first quarter of next year.

Retatrutide is designed to target three different metabolic ​hormones: GLP-1, GIP and glucagon. The company's current injectable obesity drug, Zepbound, ⁠targets GLP-1 and GIP, while rival Novo Nordisk's (NOVOb.CO), opens new tab Wegovy targets just GLP-1.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Lilly said ​an 80-week trial of adults with severe obesity and established heart disease showed average weight ​loss of 22.6% for the highest weekly dose of retatrutide.

The company said major cardiovascular events occurred less frequently than expected in both the treatment and placebo groups. But when measuring just the three ​most severe events — heart attack, stroke and death — patients on retatrutide had a 12% ​higher risk than the placebo group.

A different 80-week trial of overweight or obese patients who also had ‌type ⁠2 diabetes showed that participants given the highest dose lost 20.8% of their body weight and lowered A1C levels by 1.6%.

The most common side effects in both trials were nausea and diarrhea.

Lilly had previously announced that patients with obesity but not diabetes lost ​an average of 28.3% of ​their weight in an ⁠80-week trial of retatrutide. Positive results were also seen in Phase 3 studies of the drug's impact on knee osteoarthritis pain and ​obstructive sleep apnea.

"Across five positive Phase 3 studies, retatrutide has shown powerful ​efficacy, and ⁠we believe it could be an important future tool in the management of cardiometabolic health,” Lilly Executive Vice President Kenneth Custer said in a statement.

Lilly said it plans to submit ⁠a ​biologics license application for retatrutide to the FDA in ​the first quarter of next year. The company also said full results of the latest trials will be ​published in medical journals at a later date.

Reporting By Deena Beasley; Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles., opens new tab

© Inside Creative House / iStock via Getty Images

The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried. Novo Nordisk (NYSE:NVO | NVO Price Prediction) sued Eli Lilly (NYSE:LLY) over what it calls misleading US advertising for Zepbound, and on the news, Novo’s ADRs slipped about half a percentage point while Lilly’s stock rose. A lawsuit is supposed to be a threat, but investors read it as an admission.

You already know which side Wall Street was on going in. Lilly’s market cap sits at roughly $1.1 trillion against Novo’s roughly $167 billion. Over the past year, LLY is up 50% while NVO is down 27%. That gap is the context for everything else here.

What The Lawsuit Is Actually About The complaint, described by Bloomberg’s Madison Muller, is narrower than the headlines suggest. Lilly ran ads comparing Zepbound to an earlier, lower-dose version of Wegovy using older trial data. Novo recently secured FDA approval for a higher-dose Wegovy and argues those comparisons are now outdated. Novo did the polite corporate thing first. It sent Lilly a cease-and-desist months ago. Lilly did not change or pull the ads. So Novo went to court.

On the science, Novo has a point. The higher-dose Wegovy approval, plus Wegovy HD demonstrating nearly 21% weight loss in trials, materially changes the comparison. But litigation is a slow tool for solving a fast marketing problem, and by the time discovery starts, doctors will have written another quarter of prescriptions.

Why The Stock Reaction Tells The Real Story Muller’s reporting hit the pressure point. There is a genuine consumer perception that Zepbound is better than Wegovy, with patients walking into doctors’ offices asking for Lilly’s drug by name. That demand signal shows up on the income statement. Lilly’s blowout Q1 2026 delivered $19.8 billion in revenue, up 55.5% year over year, with Mounjaro at $8.66 billion (+125%) and Zepbound at $4.16 billion (+80%). Non-GAAP EPS came in at $8.55, beating the $6.79 consensus.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

Novo’s quarter looked different. Adjusted sales fell 4% at constant exchange rates, EPS of $6.63 missed the $6.96 consensus, and management guided full-year adjusted sales to -4% to -12% at CER. The company also telegraphed list-price cuts of roughly 50% on Wegovy and 35% on Ozempic effective January 1, 2027. When you are cutting price by half, a court filing about ad copy is not the lever that saves you.

How Novo Lost Its Lead And Whether A Lawsuit Can Win It Back Novo essentially invented the modern GLP-1 category, and then Lilly out-executed it. Lilly launched a direct-to-consumer website and cut cash-pay prices before Novo did. Muller described Novo as having “rested on their laurels a bit” while Lilly moved aggressively to out-innovate. Novo’s response has been dramatic. A new CEO in Mike Doustdar, roughly 9,000 job cuts, and a culture overhaul.

The oral pill launch shows the franchise still fights in it. Wegovy pill did $2.26 billion in its first full quarter and captured 65% of new US prescriptions in the oral GLP-1 category, with over one million patients since the January launch. That is not a company being lapped. But Lilly countered with Foundayo, its own approved oral GLP-1 pill that can be taken any time of day without food or water restrictions, and raised its 2026 revenue guidance to $82.0 billion to $85.0 billion. The analyst consensus target on LLY sits at $1,270.37 versus $47.43 for NVO. The Street’s verdict is not subtle.

The Verdict For Investors A lawsuit does not fix a perception problem, and perception is what Novo needs to change. Lilly enters this fight with a bigger, faster-growing franchise, superior head-to-head trial data on the injectable side, an approved oral pill of its own, and a stock that is up 377% over five years while Novo’s ADR is up just 7% over the same stretch. Novo is still enormously profitable, and its oral launch is real, but the burden of proof has flipped. Lilly has to keep executing. Novo has to convince patients and doctors that the newer, higher-dose Wegovy is worth switching to, and no court order will do that for them.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Investors comparing these two funds are really choosing between two different philosophies. The iShares Global Healthcare ETF (IXJ +0.60%) is a low-cost, diversified way to own the global healthcare sector. The Simplify Health Care ETF (PINK +1.49%) is an actively managed, more concentrated fund that includes innovative biotech and medtech names -- with a mission-driven twist that sets it apart from most other ETFs.

Snapshot (cost & size)MetricPINKIXJIssuerSimplifyiSharesExpense ratio0.51%0.40%1-year return (as of June 21, 2026)31.93%19.57%Dividend yield0.64%1.47%Beta0.780.52AUM$358.6 million$3.8 billionBeta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

IXJ is the more affordable option, with a 0.40% expense ratio compared to PINK's 0.51%. IXJ also pays out more for income-focused investors -- with a 1.47% dividend yield versus 0.64% for PINK.

Performance & risk comparisonMetricPINKIXJMax drawdown (3 yr)(18.77%)(18.14%)Growth of $1,000 over 3 years (total return)$1,449$1,187What's insideLaunched in 2001, the iShares Global Healthcare ETF (IXJ +0.60%) spreads its assets across 110 holdings covering the global healthcare sector. Its largest positions include Eli Lilly (LLY +2.30%) at 10.9%, Johnson & Johnson (JNJ +0.74%) at 7.0%, and Abbvie (ABBV +1.08%) at 5.1%.

The Simplify Health Care ETF (PINK +1.49%) takes a narrower, more concentrated approach, holding 58 positions. Its largest positions include Purecycle Technologies (PCT +6.08%) at 7.1%, United Therapeutics Corp (UTHR +1.23%) at 7.1%, and Novo Nordisk (NVO 0.41%) at 7.0%. PINK was launched in 2021.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsChoosing between these two funds isn’t difficult. It really comes down to what an investor wants from their healthcare allocation.

IXJ is the more conventional choice -- a diversified index fund that's cheaper to own and pays a meaningfully higher dividend, making it a reasonable core holding for investors who want steady, low-maintenance exposure to global healthcare giants like Eli Lilly, Johnson & Johnson, and AbbVie.

PINK’s more concentrated portfolio comes with a mission-oriented mandate: Every dollar of net profit the fund generates is donated to breast cancer research through Susan G. Komen, one of the largest breast cancer non-profit organizations in the country. That's unique for an ETF -- most funds simply pocket their management fees -- so PINK gives investors a way to combine sector exposure with tangible social impact, without costing much more than a typical actively managed fund.

PINK has been the stronger performer lately, posting a roughly 32% one-year return -- well ahead of IXJ's steadier, more index-like results. That gap reflects the two funds' different approaches: PINK’s concentrated, actively managed portfolio includes more innovation-driven biotech and medtech names. These types of companies can outperform sharply at times, but that also means PINK carries more single-stock and strategy risk than a broadly diversified index fund. IXJ, by design, spreads risk across more than 100 global healthcare names, which tends to smooth out returns -- for better or worse -- compared with PINK's higher-octane approach.

Investors prioritizing income and diversification who want to keep costs as low as possible are likely better served by IXJ. Those comfortable with more concentration risk in exchange for the potential of stronger returns -- and who like the idea of their fund fees supporting cancer research -- may find PINK's offering more compelling. As always, recent outperformance is not a guarantee of what comes next, so investors should weigh their own risk tolerance as heavily as recent returns.

Andy Gould has positions in AbbVie, Novo Nordisk, and United Therapeutics. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, Novo Nordisk, and United Therapeutics. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

CNBC's Jim Cramer delivers his daily Mad Dash.

Item 1 of 3 A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly, at Rock Canyon Pharmacy in Provo, Utah, U.S., March 29, 2023. REUTERS/Brendan McDermid/George Frey REFILE - QUALITY REPEAT

[1/3]A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for... Purchase Licensing Rights, opens new tab Read more

SummaryCompaniesNovo accuses Lilly of claiming its weight-loss medicines outperform Novo'sDanish drugmaker alleges Lilly violated ad and unfair competition laws in Zepbound and Mounjaro adsEli Lilly not immediately available to commentNovo, Lilly locked in battle to dominate U.S. obesity drug marketLONDON, July 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab sued rival Eli Lilly (LLY.N), opens new tab in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.

The Danish company filed the lawsuit in U.S. District Court in New Jersey, alleging ​Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns ​for obesity drug Zepbound and diabetes treatment Mounjaro.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

Novo alleges Lilly compared the highest approved doses of its ⁠medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.

Indianapolis-based ​Eli Lilly did not immediately respond to a request for comment.

"The ads are maliciously and deceptively false because Lilly knowingly cites ​outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines," Novo wrote in its complaint.

Novo and Lilly are locked in a fierce battle for dominance in the U.S. obesity drug market, which analysts expect to be worth more than $100 billion by 2030.

Novo ​was first to market with weight-loss injection Wegovy, but later lost the lead to Lilly's rival Zepbound. After replacing its CEO ​and issuing multiple profit warnings last year, Novo has landed a counterpunch with oral Wegovy, whose strong demand has held up despite the launch ‌of Lilly's ⁠competing pill.

Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and run a corrective advertising campaign. It added that it plans to seek a preliminary injunction if Lilly does not voluntarily remove the ads.

Novo is also seeking damages, including Lilly's profits that can be attributed to the ads.

Shares of Eli Lilly (LLY.N), opens new tab fell 0.5% to $1141.84 in pre-market U.S. trade, while Copenhagen-listed ​Novo Nordisk (NOVOb.CO), opens new tab shares were down 1.7% ​in afternoon trading.

'INADEQUATE DISCLAIMER' IN ⁠ADSNovo said it sent Lilly a cease-and-desist letter in April after the U.S. approved a 7.2-milligram dose of Wegovy. Lilly did not respond to the letter, Novo's general counsel John Kuckelman told ​Reuters, adding that the company instead inserted what he described as an inadequate disclaimer into the ​advertisements.

Novo says the ⁠scale of Lilly's campaign is massive. The ad campaign has been served up to consumers more than 700 million times just since Lilly modified its ad after Novo's letter in late April.

Kuckelman said Lilly's advertisements compare weight-loss results of about 50 pounds for Zepbound with ⁠about 33 ​pounds for Wegovy, even though no head-to-head trial has compared the highest approved ​doses of the medicines. He said separate late-stage trials of the highest doses showed average weight loss of about 48 pounds for Zepbound and 47 pounds for ​Wegovy.

Reporting by Maggie Fick and Michael Erman; Additional reporting by Jonathan Stempel and Christy Santhosh editing by Caroline Humer, Nia Williams and Susan Fenton

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.

Novo Nordisk podal ve Spojených státech žalobu na svého hlavního konkurenta Eli Lilly. Dánská firma tvrdí, že reklamní kampaně propagující přípravky Zepbound a Mounjaro uvádějí spotřebitele v omyl tím, že prezentují neúplné a zastaralé údaje o účinnosti konkurenčních léků Wegovy a Ozempic od Novo Nordisku. Informoval o tom server CNBC.

Zastaralé klinické studie ohledně porovnání nejvyšších dávek léků Lilly s nižšími dávkami léků Novo „vedou k nevyhnutelnému závěru, že léky Lilly jsou lepší než léky od Novo, a to není přesné“, sdělil CNBC John Kuckelman, hlavní právní zástupce skupiny Novo, jež tvrdí, že takové srovnání neodráží současný stav trhu a dostupných klinických dat.

Novo Nordisk v žalobě požaduje, aby soud Eli Lilly zakázal další šíření sporných reklam a zároveň nařídil zveřejnění opravných sdělení. Kromě toho se firma domáhá finanční náhrady škody, jejíž výše zatím nebyla specifikována.

Dánská společnost prý zaslala svému konkurentovi formální výzvu k ukončení reklamních kampaní už v dubnu, avšak bez výsledku. Pokud Lilly reklamy nestáhne dobrovolně, chce Novo v následujících dnech usilovat také o předběžné opatření, které by jejich vysílání zastavilo ještě před konečným rozhodnutím soudu.

Dánské firmě vadí zejména to, že reklamy konkurenta nezohledňují nově schválenou vysokodávkovou variantu léku Wegovy, která byla uvedena na trh letos na jaře. Podle Novo právě tato verze přináší výsledky v redukci hmotnosti, které jsou mnohem bližší účinkům Zepbound od Lilly.

„Reklamní sdělení vedou spotřebitele k závěru, že přípravky Eli Lilly jsou jednoznačně účinnější než naše léky. Domníváme se, že takový závěr není podložen aktuálními důkazy,“ stojí v žalobě.

V té je konkrétně zmíněna televizní reklama, která přímo srovnává Zepbound a Wegovy. Ve spotu zaznívá, že pacienti užívající Zepbound ztrácejí v průměru přibližně 50 liber (22,7 kg) tělesné hmotnosti, zatímco u Wegovy to je zhruba 33 liber (15 kg). Tato čísla vycházejí z klinického srovnání nejvyšších dávek přípravku Zepbound s dávkami Wegovy 1,7 mg a 2,4 mg.

Podle Novo Nordisk však novější studie ukazují, že vyšší dávka Wegovy 7,2 mg vede v průměru k úbytku hmotnosti okolo 47 liber (21,3 kg), což se podle firmy pohybuje na srovnatelné úrovni s nejnovějšími výsledky dosahovanými přípravkem Zepbound.

Dánský výrobce zároveň tvrdí, že existence této vyšší dávky je v reklamních materiálech zmíněna pouze v obtížně čitelné poznámce pod čarou, která podle něj spotřebitelům neposkytuje dostatečné informace o aktuální účinnosti léčby, píše CNBC.

Přímá studie neexistuje

Dalším argumentem Novo Nordisku je skutečnost, že dosud nebyla provedena přímá klinická studie, která by porovnávala nejvyšší komerčně dostupné dávky Wegovy a Zepbound. Podle žaloby proto Eli Lilly nemá dostatečný základ pro kategorická tvrzení o nadřazenosti svého přípravku.

„I když to bylo možné říci předtím, než byl Wegovy dostupný i v dávce 7,2 miligramu, tak dnes už to není přesné. Myslíme si, že mají právní povinnost, ale ještě důležitější je, že mají povinnost vůči pacientům sdílet přesné informace,“ dodal Kuckelman.

Zdroj foto: Novo Nordisk

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Posted by Defense World Staff on Jul 20th, 2026

Boston Common Asset Management LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 10.6% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 24,353 shares of the company’s stock after selling 2,875 shares during the period. Eli Lilly and Company comprises about 1.4% of Boston Common Asset Management LLC’s holdings, making the stock its 14th biggest holding. Boston Common Asset Management LLC’s holdings in Eli Lilly and Company were worth $22,399,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $12,976,634,000. J. Stern & Co. LLP lifted its stake in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. boosted its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. Fifth Third Bancorp boosted its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after buying an additional 1,432,069 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.1% Shares of NYSE LLY opened at $1,178.01 on Monday. The stock has a market cap of $1.11 trillion, a PE ratio of 41.85, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The company has a 50-day moving average of $1,118.87 and a 200 day moving average of $1,036.51.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue was up 55.5% on a year-over-year basis. During the same period last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

More Eli Lilly and Company News Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984 Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Analysts Set New Price Targets A number of equities analysts have commented on the company. UBS Group increased their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday, July 13th. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Read Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Company Profile (Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Further Reading Five stocks we like better than Eli Lilly and Company Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicron Technology, Inc. $MU Shares Acquired by Dimensional Fund Advisors LP

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

Posted by Defense World Staff on Jul 20th, 2026

Broderick Brian C increased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 12.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,268 shares of the company’s stock after buying an additional 1,052 shares during the quarter. Eli Lilly and Company accounts for about 1.6% of Broderick Brian C’s portfolio, making the stock its 22nd biggest holding. Broderick Brian C’s holdings in Eli Lilly and Company were worth $8,524,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Decker Wealth Management LLC acquired a new position in Eli Lilly and Company during the first quarter worth $15,856,000. Eaton Cambridge Inc. increased its stake in Eli Lilly and Company by 20.4% in the 1st quarter. Eaton Cambridge Inc. now owns 874 shares of the company’s stock valued at $804,000 after buying an additional 148 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after buying an additional 15 shares during the last quarter. S&CO Inc. lifted its position in Eli Lilly and Company by 6.5% during the 1st quarter. S&CO Inc. now owns 21,519 shares of the company’s stock worth $19,792,000 after buying an additional 1,310 shares in the last quarter. Finally, Momentum Wealth Planning LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth about $960,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes Several equities analysts have recently weighed in on LLY shares. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Truist Financial upped their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, Berenberg Bank raised their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Read Our Latest Analysis on Eli Lilly and Company

Key Headlines Impacting Eli Lilly and Company Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984 Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Eli Lilly and Company Stock Performance Shares of LLY stock opened at $1,178.01 on Monday. The company has a fifty day moving average price of $1,118.87 and a two-hundred day moving average price of $1,036.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The stock has a market cap of $1.11 trillion, a P/E ratio of 41.85, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

About Eli Lilly and Company (Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Stories Five stocks we like better than Eli Lilly and Company Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBroderick Brian C Sells 6,558 Shares of UnitedHealth Group Incorporated $UNH

Posted by Defense World Staff on Jul 19th, 2026

Dorsey Wright & Associates purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 508 shares of the company’s stock, valued at approximately $468,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Schnieders Capital Management LLC. increased its position in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in Eli Lilly and Company in the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC acquired a new stake in Eli Lilly and Company in the second quarter worth about $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades A number of brokerages have recently weighed in on LLY. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. UBS Group boosted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Royal Bank Of Canada raised their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Check Out Our Latest Analysis on LLY

Key Eli Lilly and Company News Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984 Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Eli Lilly and Company Stock Performance LLY opened at $1,178.01 on Friday. The firm has a fifty day moving average price of $1,118.87 and a 200 day moving average price of $1,036.80. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The stock has a market cap of $1.11 trillion, a P/E ratio of 41.85, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business earned $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company Profile (Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Articles Five stocks we like better than Eli Lilly and Company Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEHartline Investment Corp Has $29.93 Million Stock Holdings in Amazon.com, Inc. $AMZN

NEXT HEADLINE »Amazon.com, Inc. $AMZN is Fishman Jay A Ltd. MI’s 3rd Largest Position

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2026 Investor’s Business Daily, LLC. All Rights Reserved.

Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company. United Health Group (UNH) produced a massive earnings beat, appeasing analysts. Meanwhile, Merck (MRK) had a major cholesterol pill approved, as well. ETFs can provide powerful tools to get exposure to some of those names in one place.

Key Takeaways: LLY, UNH, and MRK have all seen good news recently, inviting investors to use healthcare ETFs for exposure. The ETFs PPH, VHF, and XLV all offer exposure to names like the above, with each providing solid returns around about 25% over the last 12 months. Looking ahead, the three funds could help investors get exposure to that good news and diversify away from AI hyperscalers. LLY’s move to buy psychedelic drug shop AtaiBeckley, for example, has helped boost its stock notably. It is up more than 8% YTD. Meanwhile, UNH’s big earnings have helped it return 25.8% YTD and 3.8% over the last month. Finally, MRK’s big pill approval saw it spike 3.27% on July 16, and 19.9% YTD.

The VanEck Pharmaceutical ETF (PPH) offers exposure to several names, including LLY and MRK. The strategy charges a 36-basis points (bps) fee to track the MVIS US Listed Pharmaceutical 25 index. The strategy offers specific targeted exposure to pharma, rather than health stocks writ large. PPH has returned 26.6% over the last 12 months. 

Other funds to watch include, for example, the Vanguard Health Care ETF (VHT) which includes all of MRK, LLY, and UNH. VHT charges a nine-bps fee to track the MSCI US IMI 25/50 Health Care index. The fund has returned 24.4% over the last 12 months, per ETF Database data. 

Finally, the State Street Health Care Select Sector SPDR ETF (XLV) also offers exposure to all three of the stocks. Charging eight bps, the fund tracks the S&P Health Care Select Sector index. In doing so, it has returned 21.5% over the last 12 months. 

See more: The ETF World Cup: How the Final 4 Single-Nation ETFs Stack Up

Together, those types of healthcare ETFs can be efficient, flexible tools to get exposure to firms like these as they spike. Especially as AI supercharges innovation and markets anticipate rate cuts potentially next year, health care and healthcare innovation can intrigue. 

For more news, information, and analysis, visit the Equity ETF Content Hub.

Today's Change

(

33.40

%) $

1.79

Current Price

$

7.15

AtaiBeckley (ATAI +33.40%), a clinical-stage mental health and psychedelic drug developer, closed at $7.15, up 33.4%. Eli Lilly’s (LLY +1.38%) announced acquisition drove the move, and investors are watching the deal terms and closing process. Trading volume reached 164.9M shares, coming in about 1,494% above its three-month average of 10.3M shares. AtaiBeckley IPO'd in 2021 and has fallen 64% since going public.

How the markets moved todayThe S&P 500 (^GSPC 0.51%) fell 0.50% to 7,535, and the Nasdaq Composite (^IXIC 1.47%) fell 1.47% to 25,882. Among clinical-stage biopharmaceuticals focused on mental health and psychedelic therapeutics, COMPASS Pathways (CMPS 6.61%) fell 6.61% to $12.43, while broader psychedelics sentiment stayed tied to AtaiBeckley’s Lilly deal.

What this means for investorsPharmaceutical behemoth Eli Lilly acquired AtaiBeckley in a purchase worth up to $3.8 billion today, sending the latter’s shares 34% higher. The deal consists of $6.75 in cash per ATAI share, as well as $2.50 in contingent value rights (CVRs) tied to two of AtaiBeckley’s treatments meeting certain milestones over the next four, five, and seven years.

Thanks to the value of these CVRs, ATAI’s $7.15 share price currently sits above the $6.75 cash portion of the deal, suggesting the market sees potential in AtaiBeckley’s psychedelic treatments reaching their various milestones. AtaiBeckley offers DMT and other psychedelic treatments for depression, anxiety, and opioid use disorder, and has seen its stock double over the last year thanks to today’s deal and the Trump administration’s positive outlook on psychedelic-based treatments.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.

Deal Includes Cash Payment And Milestone-Based RightsLilly will pay AtaiBeckley shareholders $6.75 per share in cash. Shareholders will also receive a contingent value right (CVR) worth up to an additional $2.50 per share if specified development and regulatory milestones are achieved for BPL-003 and VLS-01.

The upfront cash consideration values AtaiBeckley at approximately $2.8 billion, while the CVR could add up to about $1.0 billion in additional value.

Lilly Adds Clinical-Stage Neuroplastogen PipelineAtaiBeckley is developing a portfolio of rapid-acting neuroplastogens designed to restore synaptic plasticity—the brain’s ability to form and strengthen neural connections involved in mood regulation.

The company’s approach differs from conventional antidepressants, which primarily target neurotransmitter levels.

Its lead candidate, BPL-003 (mebufotenin benzoate), is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression.

The company is also advancing VLS-01, a buccal film formulation of DMT, in a Phase 2b clinical study.

Lead Depression Program Advances Toward Phase 3According to the companies, BPL-003 produced rapid and durable reductions in depressive symptoms in a Phase 2b study following an in-clinic treatment session lasting about two hours on average. The treatment’s benefits persisted for months.

The U.S. Food and Drug Administration has granted BPL-003 Breakthrough Therapy Designation, and the program has initiated Phase 3 activities. VLS-01 remains in Phase 2b clinical development.

Broader Mental Health PortfolioBeyond BPL-003 and VLS-01, AtaiBeckley is developing EMP-01, an (R)-MDMA HCl therapy for social anxiety disorder that is currently in Phase 2 clinical development.

The company is also advancing a discovery program focused on identifying novel, non-hallucinogenic 5-HT2AR agonists as potential mental health treatments.

ATAI Stock Price Activity: AtaiBeckley shares were up 32.93% at $7.13 at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© metamorworks / Getty Images

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026. She framed Eli Lilly’s (NYSE: LLY | LLY Price Prediction) acquisition of Atai Beckley as a bet on rewiring the brain rather than merely dampening symptoms. “Lilly says that it is acquiring psychedelic drug developer Atai Beckley, and Lilly will pay $6.75 in cash, or $2.8 billion up front, and another $1 billion if certain development and regulatory milestones are met,” Peebles said on air.

The deal structure, $2.8 billion upfront with up to $1 billion in contingent value tied to development and regulatory milestones, keeps roughly a quarter of the headline value linked to clinical execution. That matters because Atai Beckley’s lead compound, a DMT-related nasal spray for treatment-resistant depression, only just entered Phase 3, with pivotal data expected in early 2029.

Why Lilly Is Paying Up for a 2029 Readout Lilly is acquiring from a position of strength. The company reported Q1 2026 revenue of $19.80 billion, up 56% year over year, with non-GAAP EPS of $8.55. Mounjaro and Zepbound continued to drive growth, contributing $12.8 billion in combined quarterly revenue, and management raised full-year 2026 revenue guidance to $82 billion to $85 billion. CEO David Ricks highlighted four Q1 acquisitions — Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics — underscoring Lilly’s strategy of redeploying GLP-1 cash flows into pipeline expansion. The later AtaiBeckley deal extends that acquisition push into neuroscience.

Peebles zeroed in on the science. “Lilly talked about it in their press release, where they see the opportunity to make the drug more neuroplastic, potentially changing the brain and allowing for new neural pathways to develop.” That neuroplasticity thesis separates DMT-class compounds from SSRIs and gives Lilly a longer runway story while Phase 3 runs.

The Spravato Playbook at Johnson & Johnson Johnson & Johnson (NYSE: JNJ) has already validated the clinic-administered depression-treatment model. Peebles noted that the Atai Beckley nasal spray is “a little bit like J&J’s drug SPRAVATO” because it is administered in a clinic with patients monitored afterward. J&J’s SPRAVATO franchise has become a commercial proof point for supervised psychedelic-adjacent depression therapies, with growth highlighted in the company’s Neuroscience portfolio. Its Innovative Medicine segment generated $15.43 billion in Q1 2026 revenue, up 11.2% year over year.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.

Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.

GH Research: The Small-Cap Read-Through The clearest beneficiary is GH Research (NASDAQ: GHRS), which is developing GH001, an inhalable mebufotenin (5-MeO-DMT) product candidate for treatment-resistant depression (TRD). Shares jumped 13.04% on the announcement to $30.43, extending a year-to-date gain of 111.97%. The Phase 2b trial results, later published in JAMA Psychiatry, showed a placebo-adjusted MADRS reduction of 15.5 points at Day 8, with remission rates of 57.5% versus 0% for placebo. GH Research is targeting initiation of its global Phase 3/pivotal program in 2026.

For investors mapping the small-cap ripple effect of Big Pharma validation, our Small Stakes, Big Swings research walks through how to size positions in clinical-stage names carrying binary catalysts.

What to Watch Peebles put a stake in the ground on timing: “Atai Beckley’s DMT-like drug just started Phase 3. And those results are expected in early 2029.” Between now and then, the milestones triggering Lilly’s $1 billion contingent payment will drive the narrative, alongside SPRAVATO’s growth at J&J and GH Research’s Phase 3 initiation. DEA scheduling, clinic infrastructure, and payer coverage remain shared hurdles for every psychedelic depression program.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio.

Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.

Shareholders will also receive contingent value rights (CVRs) worth up to an additional $2.50 per share if specified clinical, regulatory and commercialization milestones for AtaiBeckley's lead programs are achieved, bringing the potential total equity value to about $3.8 billion.

The purchase price represents a premium of about 40% to AtaiBeckley's 30-day volume-weighted average share price through July 15, 2026, according to Lilly.

Lilly said the acquisition would strengthen its neuroscience portfolio by adding therapies designed to restore synaptic connectivity, an approach that differs from conventional antidepressants that primarily target neurotransmitter levels.

AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression. The company said the therapy demonstrated rapid and durable reductions in depressive symptoms in a Phase 2b trial and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities have begun.

The company's second most advanced program, VLS-01, is a buccal film formulation of DMT that is currently being evaluated in a Phase 2b study.

"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, executive vice president and president of Lilly Neuroscience, said in a statement.

"Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

AtaiBeckley chief executive officer and co-founder Srinivas Rao said the transaction could accelerate development of the company's pipeline.

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

Christian Angermayer, founder, largest shareholder and chairman of AtaiBeckley, said the deal represented "the best path forward for patients and shareholders."

The transaction is expected to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders, regulatory approvals and other customary closing conditions.

Apeiron Investment Group and all AtaiBeckley directors and officers have entered voting and support agreements backing the transaction. The shares covered by those agreements represent approximately 15% of the company's outstanding common stock.

Goldman Sachs is serving as Lilly's exclusive financial adviser, while Moelis & Company and Centerview Partners are advising AtaiBeckley.

Shares of AtaiBeckley were set to open 34% higher at $7.19.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio.

Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.

Shareholders will also receive contingent value rights (CVRs) worth up to an additional $2.50 per share if specified clinical, regulatory and commercialization milestones for AtaiBeckley's lead programs are achieved, bringing the potential total equity value to about $3.8 billion.

The purchase price represents a premium of about 40% to AtaiBeckley's 30-day volume-weighted average share price through July 15, 2026, according to Lilly.

Lilly said the acquisition would strengthen its neuroscience portfolio by adding therapies designed to restore synaptic connectivity, an approach that differs from conventional antidepressants that primarily target neurotransmitter levels.

AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression. The company said the therapy demonstrated rapid and durable reductions in depressive symptoms in a Phase 2b trial and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities have begun.

The company's second most advanced program, VLS-01, is a buccal film formulation of DMT that is currently being evaluated in a Phase 2b study.

"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, executive vice president and president of Lilly Neuroscience, said in a statement.

"Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

AtaiBeckley chief executive officer and co-founder Srinivas Rao said the transaction could accelerate development of the company's pipeline.

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

Christian Angermayer, founder, largest shareholder and chairman of AtaiBeckley, said the deal represented "the best path forward for patients and shareholders."

The transaction is expected to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders, regulatory approvals and other customary closing conditions.

Apeiron Investment Group and all AtaiBeckley directors and officers have entered voting and support agreements backing the transaction. The shares covered by those agreements represent approximately 15% of the company's outstanding common stock.

Goldman Sachs is serving as Lilly's exclusive financial adviser, while Moelis & Company and Centerview Partners are advising AtaiBeckley.

Shares of AtaiBeckley were set to open 34% higher at $7.19.